FHTX · Foghorn Therapeutics Inc. · Executive Compensation
$2.00
-0.01 (-0.50%)
At close · Oct 23
Return incl. dividend (before tax)
Market Cap
$118.77M
Shares
59.39M
Volume · Oct 23
486.83K
Avg daily vol (3M)
689.14K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $2,361,027 |
| Steven Bellon | Chief Science Officer | $1,199,455 |
| Alfonso Quintás-Cardama | Chief Medical Officer | $1,133,965 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kristian Humer | Chief Financial Officer | $1,888,603 |
| Adrian Gottschalk | President and Chief Executive Officer | $1,559,562 |
| Anna Rivkin | Chief Business Officer | $1,472,584 |
| Steven Bellon | Chief Science Officer | $902,212 |
| Alfonso Quintás-Cardama | Chief Medical Officer | $769,489 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $2,503,942 |
| Alfonso Quintás-Cardama | Chief Medical Officer | $1,844,535 |
| Steven Bellon | Ph.D.. Chief Scientific Officer | $1,187,494 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $5,436,444 |
| Steven Bellon | Ph.D.. Chief Scientific Officer | $2,145,667 |
| Michael LaCascia | Chief Legal Officer | $1,988,177 |
| Allan Reine | Chief Financial Officer | $1,987,269 |
| Alfonso Quintás-Cardama | Chief Medical Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $4,315,482 |
| Allan Reine | Chief Financial Officer | $2,014,346 |
| Samuel Agresta | Chief Medical Officer | $1,809,604 |
| Carl P. Decicco | Former Chief Scientific Officer | $1,809,604 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Adrian Gottschalk | President and Chief Executive Officer | $2,624,275 |
| Michael LaCascia | Chief Legal Officer | $1,988,838 |
| Carl P. Decicco | Former Chief Scientific Officer | $1,218,464 |
| Samuel Agresta | Chief Medical Officer | $1,053,797 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Carl P. Decicco | Chief Scientific Officer | $2,070,337 |
| Adrian Gottschalk | President and Chief Executive Officer | $1,305,543 |
| Samuel Agresta | Chief Medical Officer | $1,202,274 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ryan D. Maynard | Chief Financial Officer | Appointed | 2026-02-23 |
| Jeff Sacher | Treasurer | Appointed | 2025-12-04 |
| Jeff Sacher | interim Chief Financial Officer | Appointed | 2025-12-04 |
| Kristian Humer | Chief Financial Officer | Resigned | 2025-11-05 |
| Neil J. Gallagher, M.D., Ph.D. | Class II director | Appointed | 2025-05-01 |
| Stuart Duty | Class II director | Appointed | 2025-05-01 |
| Adam M. Koppel, M.D., Ph.D. | member of the board of directors | Resigned | 2024-12-30 |
| Kristian F. Humer | Chief Financial Officer | Appointed | 2024-04-16 |
| Stephen J. DiPalma | interim Chief Financial Officer | Appointed | 2024-01-17 |
| Allan Reine, M.D. | Chief Financial Officer | Resigned | 2024-01-03 |
| Thomas J. Lynch Jr., MD | Class I Director | Appointed | 2022-10-27 |
| Cigall Kadoch | member of the Board of Directors | Resigned | 2022-08-31 |
| B. Lynne Parshall | Class III Director | Appointed | 2022-08-17 |
Leadership
- Adrian Gottschalk CEO, Board Member
- Jeff Sacher CFO
- Kristian F. Humer CFO, Chief Accounting Officer
- Ryan D. Maynard CFO
- Ryan Maynard CFO
- Stephen J. DiPalma CFO
- Steven Bellon CTO
- B. Lynne Parshall Board Member
- Ian F. Smith Board Member
- Neil J. Gallagher, M.D., Ph.D. Board Member
- Stuart Duty Board Member
- Thomas J. Lynch Jr., MD Board Member